GAITHERSBURG, Md.-(BUSINESS WIRE)- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 45th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA.

What You Should Know:– GeneDx, a leader in delivering improved health outcomes through genomic insights, today announced its launch on Epic Aura, a specialty diagnostics suite within Epic’s electronic health records (EHR).– The integration allows health systems to directly order GeneDx’s genetic tests, including exome sequencing (ES), whole genome sequencing (WGS), and rapid whole genome sequencing (rWGS), within their EHR systems.Enhanced Access to Genomic TestingThe integration with Epic Aura enables healthcare providers to seamlessly access GeneDx’s diagnostic services, streamlining the ordering process and accelerating the time to diagnosis for patients. By integrating with Epic Aura, health systems can now:Order GeneDx tests directly within their EHR: This eliminates the need for manual data entry and reduces the risk of errors.This eliminates the need for manual data entry and reduces the risk of errors. Receive results seamlessly: Results are automatically transmitted back to the EHR, ensuring timely access to patient information.Results are automatically transmitted back to the EHR, ensuring timely access to patient information. Improve efficiency and workflow: Streamline the diagnostic process and improve overall efficiency for clinicians.Unmatched Experience in Genomic TestingGeneDx has extensive experience in genomic testing, having sequenced over 750,000 exomes and genomes and collected millions of phenotypic data points. This vast dataset enables GeneDx to provide accurate and comprehensive diagnostic insights.Future Expansion PlansGeneDx plans to continue expanding its partnerships with health systems and integrating with other EHR platforms to further enhance access to genomic testing. The company is also committed to advancing its genomic technologies and expanding its offerings to address a wider range of genetic conditions.“GeneDx is committed to providing patient-centered solutions and our use of Aura simplifies the process for healthcare providers to ensure the first step to treatment, an accurate and fast genetic diagnosis, is easily accessible at a patient’s bedside and in the exam room,” said Katherine Stueland, President and CEO of GeneDx